Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

761 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Adema V, Palomo L, Walter W, Mallo M, Hutter S, La Framboise T, Arenillas L, Meggendorfer M, Radivoyevitch T, Xicoy B, Pellagatti A, Haferlach C, Boultwood J, Kern W, Visconte V, Sekeres M, Barnard J, Haferlach T, Solé F, Maciejewski JP. Adema V, et al. Among authors: barnard j. EBioMedicine. 2022 Jun;80:104059. doi: 10.1016/j.ebiom.2022.104059. Epub 2022 May 23. EBioMedicine. 2022. PMID: 35617825 Free PMC article.
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, McMahon J, Makishima H, Szpurka H, Jankowska A, Jerez A, Sekeres MA, Saunthararajah Y, Advani AS, Copelan E, Koseki H, Isono K, Padgett RA, Osman S, Koide K, O'Keefe C, Maciejewski JP, Tiu RV. Visconte V, et al. Among authors: barnard j. Blood. 2012 Oct 18;120(16):3173-86. doi: 10.1182/blood-2012-05-430876. Epub 2012 Jul 23. Blood. 2012. PMID: 22826563 Free PMC article.
Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.
Visconte V, Avishai N, Mahfouz R, Tabarroki A, Cowen J, Sharghi-Moshtaghin R, Hitomi M, Rogers HJ, Hasrouni E, Phillips J, Sekeres MA, Heuer AH, Saunthararajah Y, Barnard J, Tiu RV. Visconte V, et al. Among authors: barnard j. Leukemia. 2015 Jan;29(1):188-95. doi: 10.1038/leu.2014.170. Epub 2014 May 23. Leukemia. 2015. PMID: 24854990
Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.
Visconte V, Tabarroki A, Zhang L, Parker Y, Hasrouni E, Mahfouz R, Isono K, Koseki H, Sekeres MA, Saunthararajah Y, Barnard J, Lindner D, Rogers HJ, Tiu RV. Visconte V, et al. Among authors: barnard j. J Hematol Oncol. 2014 Dec 7;7:89. doi: 10.1186/s13045-014-0089-x. J Hematol Oncol. 2014. PMID: 25481243 Free PMC article.
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation). Zeidan AM, et al. Among authors: barnard j. Am J Hematol. 2015 Nov;90(11):1036-40. doi: 10.1002/ajh.24173. Am J Hematol. 2015. PMID: 26284571 Free article.
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R; MDS Clinical Research Consortium. Zeidan AM, et al. Among authors: barnard j. Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14. Leukemia. 2016. PMID: 26464171 Free PMC article.
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS; MDS Clinical Research Consortium. Nazha A, et al. Among authors: barnard j. Leuk Res. 2016 Feb;41:43-7. doi: 10.1016/j.leukres.2015.12.007. Epub 2015 Dec 22. Leuk Res. 2016. PMID: 26777537 Free PMC article.
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA; MDS Clinical Research Consortium. Nazha A, et al. Among authors: barnard j. Haematologica. 2016 Jun;101(6):e224-7. doi: 10.3324/haematol.2015.140962. Epub 2016 Mar 18. Haematologica. 2016. PMID: 26992944 Free PMC article. Clinical Trial. No abstract available.
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA; Evans MDS Clinical Research Consortium. DeZern AE, et al. Among authors: barnard j. Leuk Lymphoma. 2017 Jun;58(6):1325-1331. doi: 10.1080/10428194.2016.1246726. Epub 2016 Oct 24. Leuk Lymphoma. 2017. PMID: 27774847 Free PMC article.
761 results